Morningside

Geneoscopy, LLC, based in Saint Louis, Missouri, specializes in developing non-invasive diagnostic tests aimed at preventing, detecting, and guiding treatment for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, the company utilizes a proprietary platform that extracts stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the effects of DNA mutations associated with the disease. Geneoscopy's technology not only enhances screening compliance but also facilitates the early detection of colorectal neoplasms, ultimately aiming to reduce morbidity and mortality linked to colorectal cancer. The company is also exploring additional applications of its technology for related gastrointestinal conditions.

ENYO Pharma SA is a clinical-stage biopharmaceutical company based in Lyon, France, that focuses on the discovery and development of innovative treatments for acute and chronic viral infections. Established in 2014 by a team of scientists from the Infectiology Research Center, the company utilizes a proprietary platform to identify intracellular therapeutic targets and develop small molecule therapeutics. ENYO Pharma's research primarily targets significant human infecting viruses, with current programs aimed at treating chronic hepatitis B and severe influenza. The company's pipeline includes a lead compound, EYP001, which modulates FXR to reduce the cccDNA reservoir and inhibit the expression of viral proteins, along with EYP002, which is in preclinical studies. With an emphasis on addressing unmet medical needs in infectious diseases and metabolic disorders, ENYO Pharma has established collaborations with prominent research institutions to enhance its drug development efforts.

Phage Pharm is a professional enterprise in the industrialization of bacteriophages.

evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniques we are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines.

AdvanCell is a clinical-stage radiopharmaceutical company focused on developing innovative cancer therapies. The company specializes in alpha-emitting isotopes, specifically 212Pb, which are attached to molecules that target tumors directly. This approach allows for the delivery of cytotoxic radiation at the molecular level, addressing significant challenges in targeted alpha therapy regarding supply reliability and scalability. By providing safe and effective treatments for various forms of cancer, AdvanCell aims to establish its therapies as a standard of care in oncology.

Adiso Therapeutics is a biopharmaceutical company focused on developing innovative treatments for inflammatory diseases. The company aims to address the limitations of current treatment options, which often fail to halt disease progression or pose significant safety risks to patients. Adiso is advancing a unique pipeline of therapies that includes small molecules and single-strain live biotherapeutic products, both designed with novel mechanisms of action. By creating these new therapies, Adiso seeks to improve patient outcomes and provide effective solutions for those suffering from debilitating inflammatory conditions.

Geneoscopy, LLC, based in Saint Louis, Missouri, specializes in developing non-invasive diagnostic tests aimed at preventing, detecting, and guiding treatment for gastrointestinal diseases, particularly colorectal cancer. Founded in 2015, the company utilizes a proprietary platform that extracts stool-derived eukaryotic RNA (seRNA) to create a multi-target RNA biomarker panel. This innovative approach allows for the identification of colorectal cancer by capturing the effects of DNA mutations associated with the disease. Geneoscopy's technology not only enhances screening compliance but also facilitates the early detection of colorectal neoplasms, ultimately aiming to reduce morbidity and mortality linked to colorectal cancer. The company is also exploring additional applications of its technology for related gastrointestinal conditions.

Robigo is a biomanufacturing company focused on developing precision microbial treatments aimed at enhancing plant health and recovering lost agricultural yields. By leveraging microbial engineering and data science, Robigo creates sustainable crop protection solutions that are designed to be more effective and safe for beneficial microbes, pollinators, humans, and the environment. This innovative approach enables farmers to improve their productivity and profitability while promoting sustainable farming practices.

Exo Therapeutics, Inc. is a drug discovery and development company focused on addressing intractable pharmaceutical targets. Founded in 2018 and based in Cambridge, Massachusetts, the company utilizes its proprietary ExoSight platform to develop a pipeline of drug candidates. These candidates are designed to bind to exosites and unique binding pockets, allowing for the reprogramming of enzyme activity to achieve targeted therapeutic effects. This innovative approach aims to provide robust treatments in areas such as oncology and inflammation, while also minimizing potential side effects for patients. By employing a precise and selective methodology, Exo Therapeutics is positioned to unlock new therapeutic possibilities for a variety of diseases.

Alamar Biosciences, founded in 2018 and based in Fremont, California, specializes in developing advanced technologies for the early detection and treatment of cancer and other diseases. The company focuses on a precision proteomics platform that enhances protein analysis and the diagnosis of various diseases through innovative antibody technologies. By facilitating the discovery of new biomarkers, Alamar aims to empower healthcare providers to identify diseases at an early stage, thereby improving potential treatment outcomes and patient care.

Amylyx Pharmaceuticals develops innovative therapies for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. The company's primary product, AMX0035, is an investigational therapy that combines two active compounds, sodium phenylbutyrate and Taurursodiol. This fixed-dose formulation aims to address mitochondrial energy crises and the accumulation of toxic proteins in the endoplasmic reticulum, which contribute to neurological decline. In addition to ALS, Amylyx's research pipeline includes potential treatments for Wolfram syndrome and Alzheimer's disease. Founded in 2013 and based in Cambridge, Massachusetts, Amylyx Pharmaceuticals is dedicated to advancing solutions for serious brain disorders.

Fount Bio is a life science company based in Cambridge, Massachusetts, focused on enhancing skin health through innovative glycopolymer research. Founded in 2018, the company develops topical products that create a long-lasting hyaluronic acid network within the skin. By addressing the delivery and biostability challenges associated with traditional formulations, Fount Bio aims to maximize the benefits of hyaluronic acid without the need for invasive injections. Its proprietary technologies are designed to support clients in creating effective skincare solutions that improve both the health and beauty of the skin.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

PhoreMost Limited is a drug discovery company based in Cambridge, United Kingdom, focused on identifying new druggable targets for cancer and other unmet diseases. Since its incorporation in 2014, the company has developed Site-Seeker, a platform that uncovers cryptic druggable sites within the human genome and connects them to therapeutic functions in live-cell contexts. This innovative approach allows PhoreMost to design small molecule drugs based on functionally validated protein fragments. By collaborating with a global network of academic and industrial partners, the company aims to bring novel targeted therapies to market more efficiently, ultimately benefiting patients through cost savings and the development of first-in-class drug discovery programs for potential licensing to pharmaceutical companies.

NewAmsterdam Pharma is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for cardio-metabolic diseases. The company aims to enhance patient care for individuals with metabolic disorders by addressing the shortcomings of currently available treatments. Its leading product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor designed to effectively lower LDL cholesterol levels while potentially overcoming the limitations associated with existing therapies.

30 Technology is a biopharmaceutical platform developer focused on enhancing the lives of patients with serious and life-threatening medical conditions. The company's platform leverages the potential of nitric oxide to create new models of care, facilitating the development of innovative treatments. By doing so, it enables healthcare professionals to improve patients' healing processes and bolster their defense mechanisms against various medical challenges.

CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga. The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.

Revolo Biotherapeutics specializes in developing innovative therapies aimed at treating autoimmune and allergic diseases by resetting the immune system for long-term disease remission. Founded in 2011 and previously known as Immune Regulation, the company focuses on creating anti-inflammatory peptides that offer significant advancements in the management of moderate to severe chronic inflammatory conditions. These peptides have the potential to modify disease progression and promote remission, providing improved treatment options for patients suffering from conditions such as asthma, atopic dermatitis, and inflammatory bowel diseases. By achieving effective long-term outcomes with less frequent dosing and without suppressing the immune system, Revolo Biotherapeutics aims to transform the landscape of immuno-inflammatory disease treatment.

F2G Ltd is a biotechnology company based in Manchester, United Kingdom, that specializes in developing innovative therapies for serious fungal diseases. Established in 1998, F2G focuses on its F3 series of antifungal compounds, particularly targeting challenging fungi such as Aspergillus and other filamentous molds that pose significant health risks. The company leverages its proprietary genomics technology, MycoBank, to identify critical gene targets in fungi, facilitating the creation of effective antifungal agents. Since its initial funding in 2002, F2G has expanded its research and development capabilities, enabling it to advance its patented compounds and contribute to addressing life-threatening fungal infections that affect individuals with compromised immune systems.

neoX BIOTECH is a biotechnology company established in 2018 and located in Beijing, China. The company specializes in the development of antigen-based cancer vaccines, leveraging a combination of artificial intelligence and biophysics to enhance drug research and development. neoX BIOTECH has created a neoantigen prediction and TCR screening platform that facilitates the discovery of effective macromolecular and multispecific drugs, particularly within the immuno-oncology sector. By characterizing protein-protein interactions, the company aims to advance early therapeutic discovery, ultimately improving treatment options for cancer patients.

Amylyx Pharmaceuticals develops innovative therapies for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. The company's primary product, AMX0035, is an investigational therapy that combines two active compounds, sodium phenylbutyrate and Taurursodiol. This fixed-dose formulation aims to address mitochondrial energy crises and the accumulation of toxic proteins in the endoplasmic reticulum, which contribute to neurological decline. In addition to ALS, Amylyx's research pipeline includes potential treatments for Wolfram syndrome and Alzheimer's disease. Founded in 2013 and based in Cambridge, Massachusetts, Amylyx Pharmaceuticals is dedicated to advancing solutions for serious brain disorders.

Heyuan Biotechnology is a biotechnology company focusing on the field of gene therapy services. They offer gene therapy vectors, gene function research, drug targets, and efficacy for the basic research of gene therapy research, among other services.

evonetix is a new spin-out company that is currently incubating in the centre of the world-renowned Cambridge cluster of high-tech and life science organisations. We are seeking to develop and commercialise a new approach to the synthesis of DNA to facilitate the fast-emerging and exciting field of synthetic biology. By employing novel techniques we are able to advance DNA synthesis to levels never before seen. Our engineering team has decades of experience developing high integrity automated systems. Our high calibre team brings together expertise from across the scientific and engineering disciplines.

Pinteon Therapeutics, founded in 2014 and headquartered in Newton, Massachusetts, is dedicated to developing innovative therapeutics aimed at slowing brain degeneration and preserving cognitive function. The company focuses on targeting Pin1, a central regulator involved in various diseases, including cancer, central nervous system disorders, and autoimmune conditions. By inhibiting or activating Pin1, Pinteon seeks to interrupt the spread of toxic tau, a protein associated with neurodegenerative diseases, thereby normalizing aberrant disease processes. This approach aims to enhance patient outcomes in areas with significant unmet medical needs, particularly in maintaining brain health.

ZielBio is an early-stage biotechnology company that identifies novel high-value disease targets and develops therapeutic interventions to improve patient outcomes. Its proprietary drug discovery platform Zielfind combines the power of functional, high throughput screening with large content data analytics to identify high-value targets. They have a promising pipeline of therapies and targets, including lead compound ZB131, a proprietary humanized monoclonal antibody against cell surface plectin (CSP) a cancer target identified through Zielfind. ZielBio was founded in 2011 and is based in Charlottesville, Virginia, United States.

MedAnnex Limited is a biotechnology company based in Edinburgh, United Kingdom, focused on developing innovative treatments for patients suffering from autoimmune diseases and cancers. Established in 2009, the company specializes in creating monoclonal antibodies, particularly annexuzlimab, which targets and inhibits annexin-A1. This therapeutic approach aims to modulate both the innate and adaptive immune systems, enhancing treatment options for physicians and improving patient outcomes. MedAnnex is committed to advancing first-in-class antibody therapies that can significantly benefit individuals affected by these challenging health conditions.

Allysta is a biotechnology company focused on developing innovative therapies for fibrosing diseases and ocular surface inflammations. The company specializes in anti-inflammatory and anti-fibrotic therapeutic peptides, aiming to address conditions such as glaucoma, ocular hypertension, and dry eye diseases. Allysta's ophthalmic system activates adiponectin to signal specific pathways, enhancing treatment efficacy. Additionally, the company is working on a small-molecule multi-kinase inhibitor designed to improve outcomes for patients suffering from these ocular conditions. Through its advancements, Allysta seeks to provide healthcare providers with effective tools to manage and treat various eye diseases.

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of small molecule therapeutics aimed at addressing unmet medical needs in autoimmunity and cancer. The company's lead candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for various autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials in systemic lupus erythematosus. In addition to KZR-616, the company is developing KZR-TBD, which targets both oncology and autoimmune disorders. Founded in 2015 and based in South San Francisco, California, Kezar Life Sciences leverages insights from protein homeostasis to advance its drug discovery efforts.

Frequency Therapeutics is a clinical-stage biotechnology company based in Woburn, Massachusetts, that aims to repair or reverse damage from various degenerative diseases by utilizing the body’s own biological mechanisms. The company employs a Progenitor Cell Activation approach, which involves the use of small molecules to activate progenitor cells and promote the regeneration of functional tissue. Its leading product candidate, FX-322, is currently undergoing phase 2a clinical trials to address the underlying causes of sensorineural hearing loss. In addition to hearing loss, Frequency Therapeutics is also exploring treatments for a range of other conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. The company has established a collaboration with Astellas Pharma for the development and commercialization of FX-322. Founded in 2014, Frequency Therapeutics focuses on disease modification without the complexities associated with genetic engineering.

Amylyx Pharmaceuticals develops innovative therapies for Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. The company's primary product, AMX0035, is an investigational therapy that combines two active compounds, sodium phenylbutyrate and Taurursodiol. This fixed-dose formulation aims to address mitochondrial energy crises and the accumulation of toxic proteins in the endoplasmic reticulum, which contribute to neurological decline. In addition to ALS, Amylyx's research pipeline includes potential treatments for Wolfram syndrome and Alzheimer's disease. Founded in 2013 and based in Cambridge, Massachusetts, Amylyx Pharmaceuticals is dedicated to advancing solutions for serious brain disorders.

ASLAN Pharmaceuticals Limited is a clinical-stage biopharmaceutical company based in Singapore, focusing on developing innovative treatments in the fields of immunology and oncology. Founded in 2010, the company is dedicated to transforming the lives of patients through its clinical portfolio, which includes ASLAN004, a monoclonal therapy aimed at treating atopic dermatitis and other immunological conditions, as well as a small molecule inhibitor directed at oncology applications. ASLAN collaborates with several partners, enhancing its research and development efforts.

Advanced Cell Diagnostics, Inc. specializes in developing and commercializing cell and tissue-based diagnostic tests aimed at enhancing personalized medicine. Utilizing its proprietary RNAscope technology, the company offers a versatile platform for multiplex fluorescent and chromogenic in situ hybridization, allowing for the detection and quantification of RNA biomarkers with single molecule sensitivity. Its product portfolio includes manual assays, reagent kits in various formats, and software tools for quantitative analysis of RNA in situ hybridization samples. The company serves pharmaceutical and biotech sectors by providing assay services that facilitate understanding of disease mechanisms and support various stages of clinical trials. Additionally, Advanced Cell Diagnostics maintains a companion diagnostic assay development program to streamline assay processes. The company's products are distributed across numerous countries and are also available for purchase online. Founded in 2007 and located in Hayward, California, Advanced Cell Diagnostics operates as a subsidiary of Bio-Techne Corp.

Kezar Life Sciences, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of small molecule therapeutics aimed at addressing unmet medical needs in autoimmunity and cancer. The company's lead candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for various autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials in systemic lupus erythematosus. In addition to KZR-616, the company is developing KZR-TBD, which targets both oncology and autoimmune disorders. Founded in 2015 and based in South San Francisco, California, Kezar Life Sciences leverages insights from protein homeostasis to advance its drug discovery efforts.

Vigeo Therapeutics is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing innovative therapeutic agents aimed at treating advanced malignant tumors. Established in 2011, the company is working on a first-in-class drug discovery pipeline that seeks to reprogram the tumor immune microenvironment to enhance cancer treatment efficacy. Their primary anti-cancer agent is a peptide fragment derived from the prosaposin protein, which plays a role in inhibiting metastasis and tumor growth by stimulating the production of an inhibitory molecule within the tumor microenvironment. Vigeo Therapeutics plans to initiate multiple combination studies to assess the effectiveness of its lead candidate, VT1021, in conjunction with chemotherapies and anti-PD-1 antibodies, ultimately aiming to improve patient outcomes across various cancer types.

Ark Biosciences is a biopharmaceutical company that is dedicated to the discovery and development of innovative therapeutics to address unmet medical need, especially in the area of respiratory viral infection and viral hepatitis, for global and China market. We strive to build a science-driven biopharmaceutical company that aims to be a leader in antiviral drug discovery and development. To achieve so, we aspire for the excellence of science and be innovative. We operate with a razor-sharp focus and aggressiveness with a timely and cost efficient manner. We create a healthy and rewarding work environment for employees, and seek a superior rate of return for investors and partners.

Aduro Biotech, a clinical-stage biopharmaceutical company founded in 2000 and based in Berkeley, California, specializes in the discovery, development, and commercialization of therapies aimed at leveraging the body's natural immune system to treat challenging diseases. The company is currently advancing several candidates, including ADU-S100, which is undergoing multiple clinical trials for various forms of cancer, including advanced solid tumors and melanoma. Additionally, Aduro is developing BION-1301, a monoclonal antibody for IgA nephropathy, and exploring the potential of CD27, a co-stimulatory receptor involved in immune response, in preclinical studies. Collaborations with prominent pharmaceutical companies and research institutions further enhance Aduro's capabilities in immunotherapy research and development.

InSilixa, Inc., headquartered in Sunnyvale, CA, is a multidisciplinary, highly motivated and highly technical team comprised of industry veterans with diverse backgrounds in semiconductor, biotechnology, medicine, and informatics. Founded in 2012, InSilixa is driven by the quest to democratize and drive down the cost of molecular diagnostics worldwide by leveraging its proprietary semiconductor-based CMOS biochip technology. To that end, the company is developing point-of-care (PoC) and near patient platforms for the delivery of low cost, high-performance, and mass-deployable solutions for DNA and protein-based diagnostic testing.

DNAtrix, Inc. is a clinical-stage biotechnology company based in Texas that specializes in developing virus-driven immunotherapies for cancer treatment. The company’s leading product, DNX-2401, is an oncolytic immunotherapy designed to target and kill glioblastoma cells, a particularly aggressive form of brain cancer. This therapy has shown promising early results, with over 35 patients treated. DNAtrix is also developing additional armed DNX viruses, specifically DNX-2440 and DNX-2450, aimed at treating various solid tumors, as well as MYX-135, which targets hematological malignancies. With a focus on harnessing modified viruses to selectively destroy cancer cells while stimulating the immune system, DNAtrix seeks to expand its platform to address other cancers, including brain metastases, ovarian, and pancreatic cancers. The company was incorporated in 2005 and maintains its headquarters in Houston, Texas, with an additional office in San Diego, California.

Aduro Biotech, a clinical-stage biopharmaceutical company founded in 2000 and based in Berkeley, California, specializes in the discovery, development, and commercialization of therapies aimed at leveraging the body's natural immune system to treat challenging diseases. The company is currently advancing several candidates, including ADU-S100, which is undergoing multiple clinical trials for various forms of cancer, including advanced solid tumors and melanoma. Additionally, Aduro is developing BION-1301, a monoclonal antibody for IgA nephropathy, and exploring the potential of CD27, a co-stimulatory receptor involved in immune response, in preclinical studies. Collaborations with prominent pharmaceutical companies and research institutions further enhance Aduro's capabilities in immunotherapy research and development.

Senhwa Biosciences, Inc. is a clinical-stage biopharmaceutical company based in New Taipei City, Taiwan, focused on developing innovative therapies for cancer treatment. The company's product pipeline includes CX-4945, currently in phase I/II trials for cholangiocarcinoma and other cancers, and CX-5461, which is being evaluated in phase I studies for advanced hematologic malignancies and solid tumors. Additionally, CX-4945 is involved in trials for advanced basal cell carcinoma and pediatric brain tumors. Founded in 2012, Senhwa aims to explore validated therapeutic targets to improve patient outcomes and advance treatments that could redefine standard care.

Argos Therapeutics, Inc. was a biotechnology company based in Durham, North Carolina, focused on developing personalized immunotherapies for cancer, infectious diseases, and autoimmune disorders. It utilized its proprietary Arcelis technology platform to create individualized treatments, including rocapuldencel-T, which was undergoing Phase III clinical trials for metastatic renal cell carcinoma, and AGS-004, in Phase II trials for human immunodeficiency virus. The company's product pipeline also included therapies aimed at transplant rejection and autoimmune conditions. Founded in 1997 and originally named Merix Bioscience, Argos Therapeutics aimed to address significant unmet medical needs in the field of immuno-oncology. However, on September 24, 2019, the company filed for Chapter 7 bankruptcy, leading to its cessation of operations.

ASLAN Pharmaceuticals Limited is a clinical-stage biopharmaceutical company based in Singapore, focusing on developing innovative treatments in the fields of immunology and oncology. Founded in 2010, the company is dedicated to transforming the lives of patients through its clinical portfolio, which includes ASLAN004, a monoclonal therapy aimed at treating atopic dermatitis and other immunological conditions, as well as a small molecule inhibitor directed at oncology applications. ASLAN collaborates with several partners, enhancing its research and development efforts.

Procarta Biosystems Ltd., established in 2007 by the scientific founders, Dr. Michael McArthur and Professor Mervyn Bibb, is a spin-out company from the John Innes Centre, Norwich, a world renowned scientific centre of excellence in plant science and microbiology. The company was initially established through Plant Bioscience Ltd (PBL), the internationally regarded group specialising in early stage technology investment and IP management, on behalf of the JIC, the Sainsbury Laboratory and the Biotechnology and Biological Sciences Research Council. Procarta received seed funding in 2008 from the Rainbow and Iceni Seedcorn Funds and is currently headquartered on the Norwich Research Park.

Advanced Cell Diagnostics, Inc. specializes in developing and commercializing cell and tissue-based diagnostic tests aimed at enhancing personalized medicine. Utilizing its proprietary RNAscope technology, the company offers a versatile platform for multiplex fluorescent and chromogenic in situ hybridization, allowing for the detection and quantification of RNA biomarkers with single molecule sensitivity. Its product portfolio includes manual assays, reagent kits in various formats, and software tools for quantitative analysis of RNA in situ hybridization samples. The company serves pharmaceutical and biotech sectors by providing assay services that facilitate understanding of disease mechanisms and support various stages of clinical trials. Additionally, Advanced Cell Diagnostics maintains a companion diagnostic assay development program to streamline assay processes. The company's products are distributed across numerous countries and are also available for purchase online. Founded in 2007 and located in Hayward, California, Advanced Cell Diagnostics operates as a subsidiary of Bio-Techne Corp.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Oxyrane UK Limited is a biopharmaceutical company focused on developing innovative enzyme replacement therapies for lysosomal storage diseases, which encompass over 40 rare inherited disorders. Established in 2006 and headquartered in Manchester, United Kingdom, the company utilizes a proprietary glycoengineering platform based on the yeast Yarrowia lipolytica to produce human lysosomal enzymes that enhance enzyme uptake and localization in patients. Oxyrane's approach aims to expedite treatment initiation and improve the chances of successful outcomes for individuals affected by these conditions. Additionally, the company operates research facilities in Ghent, Belgium, and maintains a presence in Burlington, Massachusetts.

Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, focused on developing innovative medicines for patients with serious diseases, particularly cancer and viral infections. The company is advancing several clinical-stage programs, including dociparstat sodium, a potential treatment for acute myeloid leukemia, and brincidofovir, an antiviral candidate being developed as a medical countermeasure against smallpox. Chimerix's lead antiviral candidate, CMX001, is aimed at treating life-threatening double-stranded DNA viral diseases and has shown promising results in various clinical studies involving immunocompromised patients. Additionally, the company is developing CMX157, a nucleoside analogue with activity against HIV and hepatitis B, which has completed Phase 1 trials. Chimerix has established partnerships with organizations such as the Biomedical Advanced Research and Development Authority and SymBio Pharmaceuticals to further its research and commercialization efforts. The company generates revenue through license agreements, including upfront fees, royalties, and milestone payments.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

Procarta Biosystems Ltd., established in 2007 by the scientific founders, Dr. Michael McArthur and Professor Mervyn Bibb, is a spin-out company from the John Innes Centre, Norwich, a world renowned scientific centre of excellence in plant science and microbiology. The company was initially established through Plant Bioscience Ltd (PBL), the internationally regarded group specialising in early stage technology investment and IP management, on behalf of the JIC, the Sainsbury Laboratory and the Biotechnology and Biological Sciences Research Council. Procarta received seed funding in 2008 from the Rainbow and Iceni Seedcorn Funds and is currently headquartered on the Norwich Research Park.

Cylene Pharmaceuticals, Inc., a biotech pharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs that target nucleolus and kill cancer cells. It offers nucleolus targeting agents, which are small-molecule targeted cancer therapeutic agents for carcinoid/neuroendocrine tumors and pediatric brain tumors; and serine/threonine protein kinase inhibitors. The company also provides pre-clinical stage oral drug candidates. Cylene Pharmaceuticals, Inc. was founded in 1997 as Cyternex, Inc. and changed its name to Cylene Pharmaceuticals, Inc. in October 2003. The company is based in San Diego, California.

OriGene Technologies, Inc. is a biotechnology company based in Rockville, Maryland, specializing in the development, manufacturing, and sale of genome-wide research and diagnostic products. Established in 1995, OriGene offers a comprehensive array of tools for academic, diagnostic, pharmaceutical, and biotech applications. Its product portfolio includes cDNA clones, shRNA and siRNA reagents, CRISPR/Cas9 genome editing tools, proteins, antibodies, and anatomic pathology products. Additionally, the company provides services such as gene synthesis, custom cloning, and assay development, supporting a variety of research areas including cancer biomarker research and stem cell research. OriGene's extensive resources aim to facilitate gene-based research, enabling researchers to validate antibodies and develop new drugs. The company's products are distributed globally through various channels, including online platforms.

Advanced Cell Diagnostics, Inc. specializes in developing and commercializing cell and tissue-based diagnostic tests aimed at enhancing personalized medicine. Utilizing its proprietary RNAscope technology, the company offers a versatile platform for multiplex fluorescent and chromogenic in situ hybridization, allowing for the detection and quantification of RNA biomarkers with single molecule sensitivity. Its product portfolio includes manual assays, reagent kits in various formats, and software tools for quantitative analysis of RNA in situ hybridization samples. The company serves pharmaceutical and biotech sectors by providing assay services that facilitate understanding of disease mechanisms and support various stages of clinical trials. Additionally, Advanced Cell Diagnostics maintains a companion diagnostic assay development program to streamline assay processes. The company's products are distributed across numerous countries and are also available for purchase online. Founded in 2007 and located in Hayward, California, Advanced Cell Diagnostics operates as a subsidiary of Bio-Techne Corp.

BioVex is a biotechnology company dedicated to developing and commercializing biological therapies for cancer treatment and the prevention of infectious diseases. Its primary focus is OncoVEXGM-CSF, an oncolytic vaccine that selectively targets and destroys cancer cells while sparing surrounding healthy tissue. This vaccine operates by replicating within solid tumors, leading to cancer cell death, and also stimulates a robust systemic immune response against tumors. OncoVEXGM-CSF has undergone clinical testing in over 110 patients across various solid tumors, including melanoma, head and neck cancer, breast cancer, and pancreatic cancer. The treatment has demonstrated significant efficacy, routinely eliminating tumors at the injection site and achieving overall disease responses during Phase II trials, with no reported recurrences of resolved tumors. Additionally, BioVex is developing ImmunoVEXHSV2, a vaccine aimed at preventing genital herpes.

Genocea Biosciences is a biopharmaceutical company based in Cambridge, Massachusetts, focused on the discovery and development of innovative cancer immunotherapies and vaccines. Utilizing its proprietary ATLAS platform, the company profiles patients' CD4+ and CD8+ T cell immune responses to identify potential antigens in tumors. Genocea is advancing several immuno-oncology programs, including GEN-009, an adjuvanted neoantigen peptide vaccine currently in phase I/IIa clinical trials, and GEN-011, a neoantigen adoptive T cell therapy. Additionally, the company has developed GEN-003, an immunotherapy aimed at treating genital herpes, and is working on personalized cancer vaccines through its pre-clinical immuno-oncology program. Established in 2006, Genocea aims to address significant unmet medical needs with its targeted therapeutic approaches.

HD Biosciences Inc. (HDB) is a Shanghai-based biotech company specializing in drug discovery contract research. HDB has developed extensive knowledge and comprehensive technology platforms for drug discovery including assay development, high throughput drug screening, SAR, closed-loop and hit-to-lead biology solutions, as well as natural product-based lead discovery. The Company has signed multiple-year research agreements with clients including Pfizer, Organon and other pharmaceutical and biotech clients and is an indisputable leader in high value-added biology-based drug discovery CRO business in China.